Prestige BioPharma (950210) Stock Overview

Prestige BioPharma Limited, a biopharmaceutical company, engages in the research and development and marketing of biosimilars, first-in-class antibody drugs, and vaccines. The company primarily engages in the development of biosimilars, including Trastuzumab, which is under regulatory review for breast and gastric cancer; Bevacizumab, in phase 3 clinical study for solid tumours; Adalimumab, in phase 1 clinical study for arthritis. It is developing first-in-class antibody therapeutics, such as monoclonal antibodies, bispecific antibodies, and fusion antibodies for life-threatening diseases; vaccines for COVID-19 virus; and diagnostic kits for the detection of pancreatic adenocarcinoma upregulated factor. Prestige BioPharma Limited was incorporated in 2015 and is headquartered in Singapore.

950210 Stock Information

Symbol

950210

Address

21 Biopolis RoadSingapore, 138567Singapore

Founded

Trading hours

Website

https://www.prestigebiopharma.com

Country

🇸🇬 Singapore

Phone Number

65 6924 6535

Prestige BioPharma (950210) Price Chart

Prestige BioPharma Overview: Key Details and Summary

Stock data	2023	Change
Price	$10.36	N/A
Market Cap	$619.68M	N/A
Shares Outstanding	59.84M	-0.41%
Employees	0	N/A
Shareholder Equity	546.23B	27.05%

Valuation	2023	Change
P/E Ratio	0.04	N/A
P/S Ratio	5561.06	N/A
P/B Ratio	0.00	N/A

Growth	2023	Change
Return on Equity	-0.0000	N/A

Earnings	2023	Change
Revenue	$111.43K	N/A
Earnings	-$1.97M	N/A
EPS	293.60	N/A
Earnings Yield	28.35	N/A
Gross Margin	1.00	N/A
Operating Margin	6.59	N/A
Net income margin	-17.66	N/A

Financial Strength	2023	Change
Total Assets	$510.61M	N/A
Total Debt	$58.09M	N/A
Cash on Hand	$207.53M	N/A
Debt to Equity	0.0002	120.06%
Cash to Debt	$3.57	-94.99%
Current Ratio	$2.31	-69.02%